Trial
NCT00498212
A Safety and Efficacy Study of a Single or Double Dose of HEPLISAV™ Hepatitis B Vaccine in Adults With End-Stage Renal Disease
Phase IITERMINATEDSAFETYConfidence: HIGH
Sponsor
Dynavax Technologies Corporation
Collaborators
—
Condition
Hepatitis B
Intervention
1018 ISS-HBsAg-Single
Why stopped
Voluntary halt due to an FDA Clinical Hold issued in relation to DV2-HBV-10.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-26